DMRA Damora Therapeutics Earnings and EPS analysis

  1. Stocks
  2. Healthcare
  3. NASDAQ: DMRA
  4. Earnings
?
Relative Growth: Rel. Growth: 27
Relative Strength: Rel. Strength: 99
Relative Valuation: Rel. Valuation: 74
Relative Profitability: Rel. Profitability: 0

EPS in 2026 (TTM): $7.49

Last Report Period Date: Jun 30, 2026

According to the most recent financial data from June 2026, the EPS for the trailing twelve months is $7.49. Damora Therapeutics's EPS for 2025 amounted to $3.98, marking an increase from -$18.53 in 2024. During the quarterly period ending on Jun 30, 2026, DMRA's EPS stood at -$0.39.

DMRA earnings history

Historical annual and quarterly earnings per share (EPS) data for Damora Therapeutics
EPS (TTM)
$7.49
EPS Growth YoY (Quarterly)
85%
EPS (Quarterly)
-$0.39
EPS Growth (Quarterly)
37.1%

Damora Therapeutics had an annual EPS of $3.98, indicating an increase of 121.5% from -$18.53 in 2024. The quarterly per-share earnings for the period ending Jun 30, 2026, was -$0.39, indicating a 85% increase from the same quarter last year. DMRA's 12-month EPS stands at $7.49 as of June 2026. Damora Therapeutics's annual EPS in 2024 stood at -$18.53, a 48.6% increase year-over-year.

DMRA EPS vs price chart

DMRA EPS growth history

Earnings per share growth rates over time
EPS Growth YoY (Quarterly)
85%
EPS growth YoY
121.5%
EPS growth 3Y avg
N/A
EPS growth 5Y avg
N/A

Damora Therapeutics has registered an increase in EPS of 85% during the last 12 months (YoY, quarterly).

DMRA Earnings Waterfall

Breakdown of revenue, profit and net income for Damora Therapeutics

DMRA Earnings vs Peers

What are the earnings of DMRA compared to its peers
Stock name Price to Earnings EPS grwoth 1Y EPS grwoth 3Y EPS grwoth 5Y
ORMP Oramed Pharmaceuticals Inc 1.26 418.8% N/A N/A
DMRA Damora Therapeutics Inc. 4.06 121.5% N/A N/A
OMER Omeros Corp 9.54 98.1% N/A N/A
OLMA Olema Pharmaceuticals Inc N/A 15% N/A N/A
VIVS VivoSim Labs Inc. N/A -214.7% N/A N/A
ORIC Oric Pharmaceuticals Inc N/A 19.7% N/A N/A

All data is based on quarterly TTM periods, unless otherwise specified.